Provider review
Found tirzepatide review
What Found charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
Read on Found’s own pages on November 20, 2026: cash pay per 28-day cycle: $199 the first cycle, then $339 month to month, or $269, $249 and $199 on 3-, 6- and 12-month terms. It scores 69/100 under our written v4.1 scoring guide, #7 of 22 programs scored.
What is distinctive about this programme
The single most distinctive thing about this programme
Found charges the same $169 for compounded tirzepatide, semaglutide and liraglutide on its twelve-month prepaid plan. Tirzepatide is not priced above semaglutide, which breaks the pattern across almost every other provider in this market and makes Found the lowest reported figure for standard compounded tirzepatide anywhere in our dataset.
The prepayment gap is the largest in the market
$169 on twelve months prepaid, roughly $199 on six, and $289 month-to-month. That is a 71% premium for paying monthly — where NexLife (opens nexlife.us in a new tab)'s equivalent gap is now 12% ($129 against $115, November 20, 2026) and Enhance.MD's was 18% in July. Found's headline rate is therefore conditional in a way that most published comparisons do not register.
For a patient who has already established tolerance, the twelve-month rate is genuinely the lowest reported compounded tirzepatide price available. For a patient who has never taken a GLP-1, committing twelve months upfront before knowing whether they tolerate it is a substantial bet, and Found's month-to-month alternative is more expensive than most competitors' month-to-month.
Brand pricing routes through a membership
Found's brand offerings all carry a $99 CORE membership: orforglipron at $149 medication becomes $248 all-in, the Wegovy pill $198 becomes $297, the Wegovy pen $248 becomes $347, and the Zepbound KwikPen $348 becomes $447.
Two of those are worth checking against the manufacturer before purchasing. LillyDirect sells orforglipron direct at $149 with no membership, and Zepbound at $299 to $449. Found's dataset entry also lists brand Mounjaro at $1,199 all-in — a retail-level figure, where Zepbound is the identical molecule at $299 to $449 direct.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Tirzepatide injectable | $169 | Provider-reported |
| Semaglutide injectable | $169 | Provider-reported |
| Liraglutide injectable | $169 | Provider-reported |
| Tirzepatide brand injectable, FDA-approved | $447 | Provider-reported |
Where it holds up
- Lowest reported standard compounded tirzepatide price in our dataset at $169
- Same rate across tirzepatide, semaglutide and liraglutide — unusual and favourable if you switch molecules
- Medication included and flat at all doses on the compounded plans
- Liraglutide available for patients who need a daily option
Where it does not
- The $169 rate requires twelve months paid upfront; month-to-month is $289
- A 71% month-to-month premium, the widest in our dataset
- Brand products carry a $99 membership on top of medication
- One brand listing is at retail level when a manufacturer-direct route exists for far less
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Flat across covered doses |
| Lowest captured figure | $169/mo, prepaid term |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
| Category | Points |
|---|---|
| Pricing transparency | 20 |
| Total annual cost | 20 |
| Clinical oversight | 15 |
| Pharmacy transparency | 15 |
| Support | 10 |
| Regulatory disclosure | 10 |
| Accessibility | 10 |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Found | prepaid | compounded injectable | flat at all covered doses | $169 | not verified | $169 | Commitment tier | Provider-reported | 2026-07-06 |
| Found | prepaid | compounded injectable | flat at all covered doses | $169 | not verified | $169 | Commitment tier | Provider-reported | 2026-07-06 |
| Found | prepaid | compounded injectable | flat at all covered doses | $169 | not verified | $169 | Commitment tier | Provider-reported | 2026-07-06 |
| Found | prepaid | brand injectable, FDA-approved | not recorded | $447 | not verified | $447 | Commitment tier | Provider-reported | 2026-07-06 |
How this sits against the market
The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Pharmacy and fulfilment
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where Found sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | not verified | Not answered Verification pending |
| Clinical oversight and care continuity | 20 pts | not verified | Not answered Verification pending |
| State access and operational reliability | 10 pts | not verified | Not answered Verification pending |
| Cancellation, billing and support transparency | 10 pts | not verified | Not answered Verification pending |
Questions readers actually ask
Is Found the cheapest option?
Read on its own page on November 20, 2026: cash pay per 28-day cycle: $199 the first cycle, then $339 month to month, or $269, $249 and $199 on 3-, 6- and 12-month terms; medication included.
Is compounded tirzepatide the same as Zepbound?
Found scores 69/100 under the written v4.1 scoring guide, #7 of 22 programs scored from pages read November 20–21, 2026. Its weakest category is support (5 of 10).
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- GLP-1 Data API DocumentationData
- Found vs Henry MedsComparisons
- Enhance.MD Tirzepatide ReviewProviders
Related coverage
- Form Health: what we hold
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- GLP-1s Before Surgery: Why Anaesthetists Care About Delayed Gastric Emptying
- GLP-1s and Vision: Two Different Issues That Get Conflated
- What a GLP-1 Actually Costs Over a Year, and Over Five
- GLP-1 Drug Interactions: The Three That Change Management
- Flat-Rate GLP-1 Pricing: What It Means and When It Saves Money
- Hitting a Plateau on a GLP-1: What the Evidence Says
GLP-1 Tirzepatide Review. “Found Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/providers/found/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.